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This large multi-center study investigates the relationships between genetic risk for
schizophrenia and bipolar disorder, and multi-modal endophenotypes for psychosis. The
sample included 4,242 individuals; 1,087 patients with psychosis, 822 unaffected first-
degree relatives of patients, and 2,333 controls. Endophenotypes included the P300
event-related potential (N=515), lateral ventricular volume (N=798), and the cognitive
measures block design (N=3,089), digit span (N=1,437), and the Ray Auditory Verbal
Learning Task (N=2,406). Data were collected across 11 sites in Europe and Australia; all
genotypingandgeneticanalysesweredoneat thesame laboratory in theUnitedKingdom.
Wecalculatedpolygenic risk scores for schizophrenia andbipolar disorder separately, and
used linear regression to test whether polygenic scores influenced the endophenotypes.
Results showed that higher polygenic scores for schizophrenia were associated with
poorer performance on the block design task and explained 0.2% (p=0.009) of the
variance.Associations in thesamedirectionwerefoundforbipolardisorderscores,but this
wasnotstatistically significantat the1%level (p=0.02).Theschizophreniascoreexplained
0.4%ofvariance in lateral ventricularvolumes, the largestacrossall phenotypesexamined,
although this was not significant (p=0.063). None of the remaining associations reached
significance after correction for multiple testing (with alpha at 1%). These results indicate
that common genetic variants associated with schizophrenia predict performance in
spatial visualization, providing additional evidence that thismeasure is an endophenotype
for the disorderwith shared genetic risk variants. The use of endophenotypes such as this
will help to characterize the effects of common genetic variation in psychosis.
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bipolar disorder, cognition, EEG, schizophrenia, single nucleotide polymorphism (SNP)
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1 | INTRODUCTION
Psychotic illnesses, including schizophrenia and bipolar disorder,
constitute the most severe forms of mental illnesses (WHO, 2013).
They are highly heritable, with estimates of up to 80% (Cardno et al.,
1999; Smoller & Finn, 2003; Sullivan, Kendler, & Neale, 2003), and
there is evidence for significant genetic overlap between different
psychotic diagnoses (Huang et al., 2010; Lee et al., 2013; Moskvina
et al., 2009; Purcell et al., 2009; Schulze et al., 2012). Psychosis has a
highly polygenic architecture, involving thousands of common single
nucleotide polymorphisms (SNPs) of very small individual effects that
account for an estimated 32% of the heritability in psychosis (Lee,
DeCandia, Ripke, Yang, & Wray, 2012; Lee, Yang, et al., 2012; Purcell
et al., 2009; Ripke et al., 2013; Ripke, Neale, Corvin, & Walter, 2014;
Sklar, Ripke, Scott, & Andreassen, 2011). Furthermore, large-scale
genome-wide association studies have identified more than 100 SNPs
that are significantly associated with an increased risk of developing
schizophrenia (Ripke et al., 2014) and bipolar disorder (Sklar et al.,
2011).
However, it is still largely unknown exactly how these genetic risk
variants lead to the illness, and an important goal of psychiatric genetic
research is to clarify the effects and mechanisms of these variants
(Carter et al., 2017; Geschwind & Flint, 2015; Glahn et al., 2014; Hall &
Smoller, 2010; Harrison, 2015). Endophenotypes—biological markers
that are heritable, quantitative traits associated with the illness, and
observed in unaffected relatives of patients—could help us to
understand the pathways from genes to the illness (Braff & Tamminga,
2017; Geschwind & Flint, 2015; Iacono, Vaidyanathan, Vrieze, &
Malone, 2014; Gottesman & Gould, 2003; Meyer-Lindenberg &
Weinberger, 2006; Munafò & Flint, 2014). As endophenotypes are
thought to be related to the genetic factors underlying disorders, it is
likely that a subset of psychosis associated SNPs also influence them
(Lencz et al., 2014; Toulopoulou et al., 2015).
The relationship between the genetics of endophenotypes and
that of psychosis can be investigated using polygenic risk scores, a
method that calculates the combined effect of a large number of SNPs,
each with a very subtle individual effect (Purcell et al., 2009). Several
studies have shown that such polygenic scores differ between patients
and controls, thus providing a useful tool to measure genetic liability to
psychosis in independent samples (Bramon, Pirinen, Strange, Lin, &
Spencer, 2014; Derks et al., 2012; Purcell et al., 2009; Vassos et al.,
2017). A number of studies have investigated the relationship between
endophenotypes and polygenic risk scores for schizophrenia and
bipolar disorder (Caseras, Tansey, Foley, & Linden, 2015; Hall et al.,
2015; Hubbard et al., 2016; Lencz et al., 2014; Liu et al., 2017;
McIntosh et al., 2013; Papiol et al., 2014; Terwisscha van Scheltinga,
Bakker, van Haren, Derks, Buizer-Voskamp, Boos, et al., 2013;
Terwisscha van Scheltinga, Bakker, van Haren, Derks, Buizer-
Voskamp, Cahn, et al., 2013; Van der Auwera et al., 2015; Whalley
et al., 2012, 2013, 2015). However, previous studies used a case-
control design and focused on specific endophenotypes. Here we
analyse endophenotypes across three domains—anatomical, physio-
logical and cognitive—in a large family-based sample, including
relatives who have a higher genetic load than controls but without
the confounds of the illness itself.
The included measures are all putative endophenotypes for
psychosis and were compatible across centers, thus reaching
substantial sample sizes:
 P300 event-related potential: reduced amplitude and prolonged
latency of the P300 wave have consistently been found in patients
with psychotic illnesses as well as in their unaffected relatives,
compared to controls (Bestelmeyer, Phillips, Crombie, Benson, & St.
Clair, 2009; Blackwood, St Clair, Muir, & Duffy, 1991; Bramon et al.,
2005; Díez et al., 2013; Mondragón-Maya et al., 2013; Pierson,
Jouvent, Quintin, Perez-Diaz, & Leboyer, 2000; Price et al., 2006;
Schulze et al., 2008; Turetsky et al., 2014; Weisbrod, Hill,
Niethammer, & Sauer, 1999; Winterer et al., 2003). The P300 is
thought to be a correlate of attention and working memory (Ford,
2014; Näätänen, 1990).
 Cognitive performance: deficits on cognitive tests such as digit span
(measuring working memory), block design (measuring working
memory and spatial visualization), and the Rey Auditory Verbal
Learning Task (RAVLT) immediate and delayed recall (measuring
short and long term verbal memory, respectively) are common and
persistent across psychotic disorders (Bora, Yucel, & Pantelis, 2009;
Bora & Pantelis, 2015; Gur et al., 2007; Heinrichs & Zakzanis, 1998;
Kim et al., 2015; Lee et al., 2015). Abnormalities are often observed
before the onset of the illness as well as in unaffected relatives
(Birkett et al., 2008; Forbes, Carrick, McIntosh, & Lawrie, 2009;
Glahn et al., 2006; Ivleva et al., 2012; Park & Gooding, 2014;
Reichenberg et al., 2010; Saperstein et al., 2006; Snitz, Macdonald,
& Carter, 2006).
 Lateral ventricular volume: increased ventricular volume is a highly
replicated finding in patients with psychosis compared to controls
(Boos, Aleman, Cahn, Hulshoff Pol, & Kahn, 2007; Crespo-Facorro
et al., 2009; Fannon et al., 2000; Fusar-Poli et al., 2013; Haijma et al.,
2013; Kempton, Stahl, Williams, & DeLisi, 2010; Kumra et al., 2000;
McDonald et al., 2002, 2006; Sharma et al., 1998; Shenton, Dickey,
Frumin, &McCarley, 2001; Strasser et al., 2005;Wright et al., 2000).
This enlargement has been attributed to neurodevelopmental
impairments, psychosis progression, or the effects of antipsychotic
medications (Gogtay et al., 2003; McDonald et al., 2006; Pilowsky,
Kerwin, & Murray, 1993).
Past research has found a genetic overlap between these
endophenotypes and psychosis. This includes a genetic correlation
(overlapduetogenetic factors) between theP300amplitudeandbipolar
disorder (−0.33) (Hall, Rijsdijk, Kalidindi, et al., 2007) and schizophrenia
(−0.48) (Hall, Rijsdijk, Picchioni, et al., 2007). Brain volume has also been
shown tobe genetically correlatedwith psychosis, includingwholebrain
volume (−0.36) (Rijsdijk et al., 2005), and white matter volume (−0.20)
(van der Schot et al., 2009). Similarly, findings indicate a genetic
correlation between psychosis and cognition. Toulopoulou et al. (2007)
found genetic correlations between schizophrenia andworkingmemory
(−0.79), perceptual organization (−0.61), verbal comprehension (−0.34),
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and IQ (−0.75), and Georgiades et al. (2016) saw genetic correlations
between bipolar disorder and working memory (0.33), verbal learning
(−0.46), and IQ (−0.51).
The aim of this study is to test whether polygenic risk scores for
schizophrenia and bipolar disorder influence these multi-modal
psychosis endophenotypes, in a large international sample of patients
with psychosis, their unaffected first-degree relatives, and healthy
controls.
2 | METHODS
2.1 | Sample and clinical assessment
The total sample in this study included 4,242 participants of European
ancestry: 1,087 patients with psychotic illnesses (see Table 1 for
breakdown of diagnoses), 822 unaffected first degree relatives of
probands (with no personal history of a psychotic illness), and 2,333
unaffected controls (with no personal or family history of a psychotic
illness). Relatives and controls were not excluded if they had a personal
history of non-psychotic psychiatric disorders (such as depression or
anxiety), provided they were well and off psychotropic medication at
the time of testing and for the preceding 12 months. This was to avoid
recruiting a biased “super healthy” control group, unrepresentative of
the general populations.
To confirm or rule out a DSM-IV (APA, 1994) diagnosis, all
participants underwent a structured clinical interview with either the
Comprehensive Assessment of Symptoms and History (CASH;
Andreasen, Flaum, & Arndt, 1992), the Structured Clinical Interview
for DSMDisorders (SCID; Spitzer,Williams, Gibbon, & First, 1992), the
Schedule for Affective Disorders and Schizophrenia (SADS; Endicott &
Spitzer, 1978) or the Schedule for Clinical Assessment in Neuropsy-
chiatry, Version 2.0 (SCAN; Wing et al., 1990). Participants were
excluded if they had a history of neurologic disease or a loss of
consciousness due to a head injury.
Recruitment occurred across 11 locations in Australia and Europe
(Germany, The Netherlands, Spain, and the United Kingdom). See
Supplementary Materials for a summary of the data collected from
each site. Participants provided written informed consent, and the
study was approved by the respective ethical committees at each of
the 11 participating centers.
2.2 | Neuropsychological assessments
The Wechsler Adult Intelligence Scale, revised version (WAIS-R;
Wechsler, 1981) or third edition (WAIS-III; Wechsler, 1997), were
administered to participants. Performance on two subtests was used
for analyses: the combined forward and backward digit span
(measuring attention and working memory) and block design
(measuring spatial visualization). The Rey Auditory Verbal Learning
Test (RAVLT; Rey, 1964), including both immediate and delayed recall
(assessing short- and long-term verbal memory, respectively), was also
administered. Higher scores on the cognitive tasks indicate better
performance. Additional information on themethodology for each site
contributing data is reported elsewhere (Crespo-Facorro et al., 2007;
González-Blanch et al., 2007; Johnstone, Ebmeier, Miller, Owens, &
Lawrie, 2005; Korver, Quee, Boos, Simons, & de Haan, 2012;
Toulopoulou et al., 2010;Walters et al., 2010;Waters, Price, Dragović,
& Jablensky, 2009).
2.3 | EEG data collection and processing
Electrophysiological data were obtained from three sites (Table S1).
EEG data acquisition and processing varied slightly between sites and
are summarized below. The full methods for each site are reported
elsewhere (Bramon et al., 2005; Hall et al., 2006; Price et al., 2006;
Waters et al., 2009; Weisbrod et al., 1999).
In summary, EEG was collected from 17 to 20 electrodes placed
according to the International 10/20 system (Jasper, 1958). The P300
event related potential was obtained using a standard two-tone
frequency deviant auditory oddball paradigm, with standard (“non-
target”) tones of 1,000Hz and rare (“target”) tones of 1,500Hz. The
number of tones presented varied from 150 to 800, the tones were 80
or 97 dB, lasted for 20–50ms, and the inter-stimulus interval was
between 1 and 2 s. The majority of participants (90%) were asked to
press a button in response to “target” stimuli, but a subset were asked
to close their eyes and count “target” stimuli in their heads. Excluding
the 10% of participants receiving different instructions does not
change the results.
The datawere continuously recorded in one of threeways: 500 Hz
sampling rate and 0.03–120Hz band pass filter; 200Hz sampling rate
and 0.05–30Hz band pass filter; or 400Hz sampling rate and 70Hz
low-pass filter. Linked earlobes or mastoids were used as reference
and vertical, and in most cases also horizontal, electro-oculographs
were recorded at each site and used to correct for eye-blink artefacts
using regression based weighting coefficients (Semlitsch, Anderer,
Schuster, & Presslich, 1986). After additional manual checks, artefact-
free epochs were included and baseline corrected before averaging.
The averaged waveforms to correctly detected targets were then
filtered using 0.03 or 0.05Hz high-pass and 30 or 45 Hz low-pass
filters. The peak amplitude and latency of the P300 were measured
at electrode location PZ (parietal midline), within the range of
250–550ms post-stimulus.
2.4 | MRI data collection and processing
MRI data acquisition and image processing varied between sites; see
previous publications and the Supplementary Materials for an outline
of the methods used for each center (Collip et al., 2013; Crespo-
Facorro et al., 2009; Dutt et al., 2009; Frangou et al., 1997; Habets,
Marcelis, Gronenschild, Drukker, & Van Os, 2011; Hulshoff Pol et al.,
2002; Lawrie et al., 1999; Mata et al., 2009; McDonald et al., 2002;
Schnack et al., 2001; Schulze et al., 2006; Steel et al., 2002; Whalley
et al., 1999; Wobrock et al., 2009). Field strengths included 1, 1.5, or
3 T. Lateral ventricular volumes were measured using automatic or
semi-automatic region of interest analyses, and included the body,
frontal, occipital, and temporal horns.
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2.5 | Genotyping methods
DNA was obtained from blood for all participants across each center,
and sent to the Wellcome Trust Sanger Institute (Cambridge, United
Kingdom). Samples were genotyped with the Genome-wide Human
SNP Array 6.0 at the Affymetrix Services Laboratory (www.affymetrix.
com). We applied standard quality control procedures, phasing and
imputation, and adjustments for population structure as described in
the Supplementary Materials and in Bramon et al. (2014).
2.6 | Polygenic score analysis
Following the method described in Purcell et al. (2009), polygenic risk
profile scores were calculated separately for schizophrenia and bipolar
disorder. Summary data from the most recent Psychiatric Genomics
Consortium genome-wide association studies for schizophrenia
(PGC2) (Ripke et al., 2014) and bipolar disorder (Sklar et al., 2011)
were used. In both cases, we used data from the Psychiatric Genomics
Consortium that did not overlap with the sample used in the current
study. For schizophrenia polygenic scores, the discovery sample
included 31,658 cases and 42,022 controls (Ripke et al., 2014), and for
bipolar disorder, the discovery sample included 7,481 cases and 9,250
controls (Sklar et al., 2011).
Polygenic scores for each individual were calculated using PLINK
(Purcell et al., 2007), from the number of risk alleles carried for each
selected SNP (i.e., 0, 1, or 2), weighted by the log(OR) provided by the
Psychiatric Genomics Consortium, and averaged across all SNPs. SNPs
were selected from the Psychiatric Genomics Consortium's panel using
six different significance thresholds (pT < 5 × 10
−08, 0.001, 0.05, 0.1,
0.5, 1), hence including an increasing number of SNPs the more liberal
the threshold (see Supplementary Materials for the number of SNPs
included at each threshold).
2.7 | Statistical analyses
Linear regression analyses were performed to test whether schizo-
phrenia and/or bipolar disorder polygenic scores influence endophe-
notypes for psychosis. These included the P300 event related
potential (amplitude and latency), lateral ventricular volume, and
measures of cognition (digit span, block design, and the Rey Auditory
Verbal Learning Task—RAVLT immediate and delayed recall).
Endophenotype measures were standardized for each site
separately (using the overall means and standard deviations within
each site) to control for differences between the centers. Covariates
included in all analyseswere clinical group (patient, relative, or control),
study site, the first three population structure principal components,
age, and gender. Because the sample included related individuals,
robust standard errors were used to account for effects of clustering
within families. This specifies that the standard errors allow for
intragroup correlation; that is, the observations are independent
between families (clusters) but not necessarily within families. The
change in R2 between a model only including the covariates and a
model including covariates plus the polygenic score is reported, which
represents the additional proportion of the variance explained by the
polygenic risk score.
Linear regression analyses were performed for each endopheno-
type using the entire sample—patients with psychosis, unaffected
relatives of probands, and controls—examining the associations with
polygenic score at the different significance thresholds of the
TABLE 1 sample characteristics (N = 4242)
Total sample Controls Unaffected relatives Patients with psychosis
Sample size (N, %) 4,242 2,333 (55.0%) 822 (19.4%) 1,087 (25.6%)
Age (mean years ± SD) 42.5 (±15.8) 45.7 (±16.3) 45.27 (±15.65) 33.48 (±10.39)
Age range (years) 16–85 16–84 16–85 16–79
Gender (% female) 48.5% 52.0% 60.0% 32.4%
Diagnoses (N)
Schizophrenia 703 – – 703
Bipolar I disorder 105 – – 105
Psychosis NOS 86 – – 86
Schizophreniform disorder 68 – – 68
Schizoaffective disorder 60 – – 60
Brief psychotic disorder 40 – – 40
Other psychotic illness 25 – – 25
Depression 273 137 136 –
Anxiety disorder 47 15 32 –
Other non-psychotic illness 41 20 21 –
No psychiatric illness 2,794 2,161 633 –
SD, standard deviation; NOS, not otherwise specified; RAVLT, Rey auditory verbal learning task.
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Psychiatric Genomics Consortium's SNP list. This was done separately
for both the schizophrenia and bipolar disorder polygenic scores.
Although we tested seven endophenotypes, we know that
measurements within domains are correlated (correlation matrices
are presented in the SupplementaryMaterials) and thus a correction of
p-values by seven tests through Bonferroni or other methods was
deemed too stringent for a hypothesis-driven study such as this
(Perneger, 1998; Rothman, 1990; Savitz & Olshan, 1995). We,
therefore, corrected for three domains (EEG, MRI, cognition), with a
corrected significance threshold of 0.05/3 = 0.0167, that we rounded
to the slightly more stringent cut-off of p < 0.01. We report the
uncorrected p values for all analyses conducted throughout this study,
but we highlight as significant and showing sufficient evidence of
association only those surviving the correction. Statistical analyses
were conducted using STATA version 13 (www.stata.com).
3 | RESULTS
3.1 | Sample characteristics
Demographic information and mean values of the different endophe-
notypes are presented in Table 1. The patient group was significantly
younger compared to both relatives (mean diff. = 11.8, p < 0.001) and
controls (mean diff. = 12.3, p < 0.001), whereas relatives and controls
did not differ in mean age (mean diff. = 0.5, p = 0.4). There were more
males in the patient group compared to both the control (χ2 = 114.4,
p < 0.001) and relative groups (χ2 = 144.4, p < 0.001). The group of
relatives contained more female participants than the control group
(χ2 = 15.8, p < 0.001). Age and gender are included as covariates in all
analyses.
Mean scores on the different endophenotypes followed the
expected pattern of improving performance from patients, through to
relatives and controls. See Supplementary Materials for statistics of
group differences and distributions across groups, after correcting for
covariates of age, gender, and study site.
3.2 | Schizophrenia polygenic risk score analysis
The schizophrenia polygenic score differed significantly between the
three groups (F(2,3184) = 86.6, p = 2.3 × 10−37; controls vs. patients
p = 1.6 × 10−35, controls vs. relatives p = 3.6 × 10−4, patients vs.
relatives p = 1.1 × 10−16), with patients having the highest scores,
followed by relatives and lastly controls (see Figure 1, left panel).
The polygenic score for schizophrenia predicted scores on the
block design task at the SNP p-value threshold of pT< 0.05, with 0.20%
of variance explained (p = 0.009). A higher polygenic score was
associated with poorer performance on the block design task. The
polygenic score for schizophrenia explained 0.4% of the variance in
lateral ventricular volumes, the highest percentage across all
phenotypes we examined; although this result was not significant
(p = 0.063). No other associations reached significance after correcting
for multiple testing. These results are shown in Figure 2a (for full
results, see Supplementary Materials).
3.3 | Bipolar disorder polygenic risk score analysis
The bipolar disorder polygenic score differed significantly between the
three groups (F(2,3184) = 21.8, p = 4.0 × 10−10; controls vs. patients
p = 4.9 × 10−11, controls vs. relatives p = 6.1 × 10−4, patients vs.
relatives p = 2.8 × 10−3), with patients having the highest scores,
followed by relatives and lastly controls (see Figure 1, right panel).
The polygenic score for bipolar disorder explained 0.17% of the
variance in block design (at pT< 5 × 10
−8), although this did not reach
significance after correction for multiple testing (p = 0.02). The
proportions of variances explained by the bipolar disorder polygenic
score were all <0.2% (and mostly below 0.1%), and none of the other
associations were significant after correcting for multiple testing.
These results are shown in Figure 2b (for full results see Supplementary
Materials).
3.4 | Additional analyses
Given the fact that we are including both controls and relatives that are
young enough to potentially yet develop a psychotic illness, we have
repeated the analyses excluding relatives and controls under the age of
30 (202 relatives and 551 controls). This resulted in a reduction in the
total sample size of 17.8% to 3489 participants. This analysis did not
change the overall conclusions of the study, and has been described in
the Supplementary Materials.
4 | DISCUSSION
The aim of this study was to investigate whether polygenic risk
scores for schizophrenia and bipolar disorder—based on the
latest mega-analyses from the Psychiatric Genomics Consortium—
influence a range of endophenotypes for psychosis in this large
international sample. This included the P300 event related potential
amplitude and latency, lateral ventricular volume, and measures of
cognition (block design, digit span, and the Rey Auditory Verbal
Learning Task). Higher schizophrenia polygenic scores predicted
poorer performance on the block design task, with 0.20% of the
variance explained.
Several studies have investigated the relationship between
cognition and polygenic score for schizophrenia. Terwisscha van
Scheltinga, Bakker, van Haren, Derks, Buizer-Voskamp, Cahn, et al.
(2013) failed to show an association with intelligence in a sample of
672 patients with schizophrenia and controls, but McIntosh et al.
(2013) found an association with cognitive change between the ages
of 11 and 70 in 937 controls. Further, in a large sample of 4,900
controls, Lencz et al. (2014) saw an association between schizo-
phrenia polygenic score and general cognitive ability. Lencz et al.
(2014) also calculated polygenic score for cognition (i.e., including
SNPs associated with cognitive performance) in healthy controls,
and used this to significantly predict disease status in a sample of
over 5,000 patients with schizophrenia and 5,800 controls, with
∼0.5% of the variance in disease risk explained by the cognitive
polygenic score.
6 | RANLUND ET AL.
Hence, research suggests that there is a genetic overlap between
cognitive performance and schizophrenia susceptibility (Lencz et al.,
2014; Toulopoulou et al., 2010, 2015), and our finding with the block
design task is in line with this. This provides support for the notion that
this measure of spatial visualization is an endophenotype for
schizophrenia, and that genetic risk variants are shared between the
two traits. However, there was no association between measures of
working and verbal memory and this polygenic score, and furthermore,
noassociations reached significance for bipolar disorder polygenic score
after correction formultiple testing. This couldbedue to a lackof power,
as these genetic effects are likely to be subtle as discussed below. It is
nevertheless interesting that for bipolar disorder, the association with
block design approached significance at the most stringent threshold;
this is the genome-wide significant threshold and included only four
SNPs that have been associated with bipolar disorder. These did not
overlap with SNPs included in the schizophrenia score at this threshold,
thus indicating a potential genetic overlap between block design
impairment and bipolar disorder risk. Cognition has also been put
forward as a possible endophenotype for bipolar disorder (Gkintoni,
Pallis, Bitsios, & Giakoumaki, 2017; Miskowiak et al., 2017; Trotta,
Murray, &MacCabe, 2015), although the evidence ismuchmore limited
than for schizophrenia and further research is required.
We did not find an association between polygenic risk scores for
schizophrenia and bipolar disorder and the P300 event related
potential. Similarly to this, studies by Hall et al. (2015) in a sample
of 392 patients with schizophrenia and controls, and Liu et al. (2017)
including a community-based sample of over 4,000 individuals, both
failed to show associations between the P300 and polygenic score for
schizophrenia. Nevertheless, research has suggested that the P300 has
a significant genetic component. Abnormalities in unaffected first-
degree relatives of patients have been identified (Schulze et al., 2008;
Thaker, 2008), its heritability is around 60% (Hall et al., 2006; van
Beijsterveldt & van Baal, 2002), and about 27% of variance in P300
amplitude can be accounted for by common genetic variation (Malone
et al., 2014). Furthermore, a significant genetic overlap of about 34%
between the P300 amplitude and bipolar disorder has been observed
(Hall, Rijsdijk, Kalidindi, et al., 2007). It is possible that the overlap in
common variants involved in both psychosis and the P300 is small,
suggesting subtle effect sizes that are difficult to detect with very large
samples required.
As for the influence of polygenic scores on measures of brain
volumes, Terwisscha van Scheltinga, Bakker, vanHaren, Derks, Buizer-
Voskamp, Boos, et al. (2013) and Papiol et al. (2014) both looked at
total brain, white and gray matter volumes, and associations with
FIGURE 1 Distribution of schizophrenia (left panel) and bipolar disorder (right panel) polygenic scores at the most liberal SNP p-value
threshold (pT< 1), for the whole sample (upper panel) and across the three groups (lower panel) [Color figure can be viewed at
wileyonlinelibrary.com]
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schizophrenia polygenic score based on an early version of the
Psychiatric Genomics Consortium data (including about 9,400 cases of
schizophrenia); the former found a significant association whereas the
latter did not. Van der Auwera et al. (2015) used data from the latest
Psychiatric Genomics Consortium analysis (including nearly 37,000
patients with schizophrenia), and a test sample of 1,470 healthy
controls. They failed to show an association between schizophrenia
polygenic score and whole brain, gray or white matter volumes (Van
der Auwera et al., 2015). Furthermore, in line with our current findings,
Caseras et al. (2015) did not find an association between schizophrenia
or bipolar disorder polygenic scores and lateral ventricular volume, and
Franke et al. (2016) found no evidence of genetic overlap between
schizophrenia and a set of subcortical brain structures.
Ventricular volume has a genetic basis with heritability estimates
ranging from 30% to 70% (Carmelli, Swan, DeCarli, & Reed, 2002;
Kremen et al., 2010, 2012; Peper et al., 2009; Schmitt et al., 2007).
McDonald et al. (2002) found increased volumes in unaffected
relatives of individuals with schizophrenia in families with more than
one affected member, but not in relatives from families with only a
single known case. In a meta-analysis of 1,065 unaffected relatives of
patients with and 1,100 healthy controls, Boos, et al. (2007) did not
find an overall effect in relatives, which is consistent with group
comparisons in our sample. Enlargement of cerebral ventricles remains
the best replicated biomarker in schizophrenia and bipolar disorder.
The samples investigating unaffected relatives including our own are
of modest size and probably have limited power to detect anatomical
changes, which we would expect to be much milder than those
observed among patients. Of course, the ventricular enlargement
described in psychosis might also be due to illness progression, or to
the effects of treatment with antipsychotic medication over time.
Nevertheless, it is striking that the variance explained by the
schizophrenia scores is larger for ventricular volume than for any
other endophenotype we examined, with p-values approaching
significance, and the question remains whether with larger samples
one might see an association.
Although research has shown that there is a genetic component
contributing to variability in the biomarkers investigated here, these
are all complex (multifactorial and heterogeneous) phenotypes, and
environmental factors play important roles too. Furthermore, all
endophenotypes are likely to have complex genetic influences,
including a substantial polygenicity (de Geus, 2014; Geschwind &
Flint, 2015; Munafò & Flint, 2014; Rees, O’Donovan, & Owen, 2015),
and only a subset of SNPs associatedwith psychosis will also be related
to particular endophenotypes, and vice versa, suggesting that effect
sizes for the associations of overlapping genetic factors will be small
(Lencz et al., 2014). This has indeed been found for the phenotypes
investigated so far, with the amount of variance explained by polygenic
scores mostly below 1% (Hall et al., 2015; Lencz et al., 2014; McIntosh
et al., 2013; Papiol et al., 2014; Terwisscha van Scheltinga, Bakker, van
Haren, Derks, Buizer-Voskamp, Boos, et al., 2013; Terwisscha van
Scheltinga, Bakker, van Haren, Derks, Buizer-Voskamp, Cahn, et al.,
2013; Van der Auwera et al., 2015; Whalley et al., 2012, 2013, 2015).
Hence, very large samples are needed to detect such subtle effects. In
future, once there aremore comparable studies using similarmeasures,
a meta-analysis of research into associations between endopheno-
types and polygenic risk scores for psychosis would be an excellent
way of synthesising findings and judging where to focus future
research efforts.
That the only endophenotype reaching significance (the block
design task) wasmeasured in larger samples suggests that powermight
indeed be an issue. For the EEG and MRI measures, that are more
laborious to obtain, sample sizes in this study ranged from just over
500 to about 800, which means that a variance explained of 1–1.5% or
higher could be detected, suggesting power was limited for these
phenotypes. For the cognitive endophenotypes, however, the sample
sizes were larger and variances explained of 0.25–0.55% or higher
could be detected (see Supplementary Materials for details of this
power analysis).
A limitation of this study was the heterogeneity of methods
between study sites in terms of endophenotype collection, processing
and analysis. This might have added noise to the data and thus reduce
power to detect any true effects. However, an important strength was
FIGURE 2 Variance explained (R2) by schizophrenia (a) and
bipolar disorder (b) polygenic scores across endophenotypes. The
bars represent different single nucleotide polymorphism (SNP)
p-value thresholds (pT). Where a bar appears missing this is because
the variance explained is too low to display given the scale used in
the figure. The lowest p-value for each endophenotype is displayed
above the corresponding bar; the p-value in bold shows a significant
finding. RAVLT, Rey auditory verbal learning task; imm, immediate
recall; del, delayed recall [Color figure can be viewed at
wileyonlinelibrary.com]
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that genotyping of all samples was done at the same laboratory using
the same platform, and that all genetic analyses and quality control
were completed in a unified way. Furthermore, it is precisely through
this multi-center effort that we were able to achieve a very large
sample, a key strength of this study. As the Psychiatric Genomics
Consortium's work shows, large international collaborations are
essential in genetic studies of common diseases and traits (Lee
et al., 2013; Ripke et al., 2014; Sklar et al., 2011; Smoller et al., 2013).
Although common variants are thought to explain up to 30% of
heritability in psychosis, genomewide association studies to date have
only significantly identified about 3% of this (Fernandes et al., 2013;
Lee, DeCandia, et al., 2012). More can be captured by calculating
polygenic scores, although false positives will also be included (Iyegbe,
Campbell, Butler, Ajnakina, & Sham, 2014; Wray et al., 2014). It is
important to note that a larger discovery sample used to calculate
polygenic scores is likely to include a higher proportion of true positive
hits, and hence lead to enhanced performance of the polygenic scores
as predictors of disease risk (Chatterjee et al., 2013; Dudbridge, 2013;
Plomin, 2013; Wray et al., 2014). Compared to the discovery sample
size used to calculate the schizophrenia polygenic score (including
about 31,700 cases Ripke et al., 2014) the discovery sample for the
bipolar disorder score was more than four times smaller—including
only about 7,500 cases (Sklar et al., 2011)—and consequently this is the
most compelling explanation of the lack of findings with the bipolar
disorder polygenic score.
Importantly, there are highly significant differences in polygenic
scores between the clinical groups, both in this sample and in previous
studies (Bramon et al., 2014; Derks et al., 2012; Purcell et al., 2009;
Ripke et al., 2014), indicating that this measure does capture genetic
variants that differ between patients, unaffected relatives, and healthy
controls. However, currently their predictive power is still low, and
polygenic scores are not able to predict illness status accurately
enough to be used in clinical practice. This would require very large
discovery data sets, a large catalogue of genetic risk variants
(potentially including both common and rare variants), and most likely
the inclusion of a combination of genetic and non-genetic risk factors
such as cognition, brain imaging, or family history, as well as age and
gender (Chatterjee et al., 2013; Dima&Breen, 2015; Dudbridge, 2013;
Iyegbe et al., 2014;McCarroll &Hyman, 2013;Wray, Yang, Goddard, &
Visscher, 2010).
In future, as our understanding of the genetic architecture of
psychosis improves, and as discovery samples become larger, the
performance of the polygenic scores is likely to be further enhanced.
Polygenic scores could then be useful for testing hypotheses about the
functional effects of risk variants, or to investigate the associations
between disease risk and severity of illness, symptoms dimensions, and
treatment or functional outcomes. This method could potentially be
used to stratify populations into groups with shared genetic features,
or to identify individuals at high-risk of developing psychosis who
would benefit from early therapeutic interventions (Maier et al., 2015;
Wray et al., 2014). Furthermore, using polygenic scores based on
selected genetic risk variants clustering on specific functional path-
ways, rather than a broad selection of SNPs, could become beneficial in
the investigation of the specific effects that genetic risk factors for
psychosis have on brain function/structure and cognition.
In conclusion, results from this large multi-center study indicate
that the combined effect of common genetic risk variants for
schizophrenia is associated with spatial visualization (as measured
by the block design task), providing further evidence that this measure
is an endophenotype for the disorder with shared genetic risk variants.
No other associations between polygenic scores for schizophrenia or
bipolar disorder and endophenotypes reached significance, possibly
due to a lack of power, with larger samples needed to detect these
small effects. As discovery samples get larger, and additional and
better targeted genetic information is included, the performance of
polygenic scores will be further enhanced. Larger association studies
using these scores on deeply phenotyped samples may in future
provide a promising approach to investigate the effects and
mechanisms of genetic risk variants for psychosis.
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